Genmab — November 2019
-
ash: Conclusions: Subcutaneously administered GEN3013, a potent CD3×CD20 bsAb, shows good tolerability and early evidence of clinical activity at low dose levels in heavily pretreated pts with relapsed or refractory B-NHL. All CRS events were non-severe and did not lead to discontinuation. No DLTs were observed. Dose escalation is ongoing; updated data will be presented. Dose expansion will begin upon determining the recommended Phase 2 dose (RP2D) (NCT03625037).
-
-
758 First-in-Human, Phase 1/2 Trial to Assess the Safety and Clinical Activity of Subcutaneous GEN3013 (DuoBody
-CD3×CD20) in B-Cell Non-Hodgkin Lymphomas https://ash.confex.com/ash/2019/webprogram/Paper121460.html -
4066 Duobody-CD3xCD20 Induces Potent Anti-Tumor Activity in Malignant Lymph Node B Cells from Patients with DLBCL, FL and MCL Ex Vivo, Irrespective of Prior Treatment with CD20 Monoclonal Antibodies https://ash.confex.com/ash/2019/webprogram/Paper125765.html
-
-
-
Mim8 utilized the Duobody
platform / Novo Nordisk / hemophilia A https://ash.confex.com/ash/2019/webprogram/Paper122817.html -
@ The Note 10.30. Jeg har længe og er stadig yderst positiv på Genmab, og der kommer jo den ene gode historie efter den anden. Vi kan jo og har tidligere set, at andre "store" spillere har en trading interesse i aktien både på den korte og mellemlange bane, og det kan give udsving, som river de nervøse midt over.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind